2022 - Improving Clinical Attrition and Decision-Making with Artificial Intelligence

This webinar will illustrate how technology can ensure researchers get a thorough, bird’s eye view of all available evidence, enabling faster, better-informed decisions from target identification through to Phase III clinical trials. This decreases clinical attrition, saves businesses a huge amount of time and money and ultimately brings more lifesaving medicines to market.
It is well documented that only 10 percent of clinical candidates make it to market. This is a startlingly low figure, especially when millions of dollars and years of development that go into a single candidate are taken into consideration.
The reasons for failure are known, with one of the most critical being poor target validation in the early stages of drug development. It has been shown that success rates increase when better informed decisions are made early on. To improve clinical attrition, it is therefore imperative to improve decision-making in R&D.
Artificial Intelligence (AI) has been transformative for many industries such as banking, automotive and transportation. Drug development however has not been impacted to the same degree. This is in part due to the drug development process being lengthy and complex, making it inherently difficult to integrate innovations. However, by using AI to influence key decision points along the R&D value chain, it is possible to unlock technology’s real value.
Register to learn how AI can augment and empower humans to make better quality decisions in R&D, leading to improved clinical attrition.